Carotid intima-media thickness in patients with inflammatory bowel disease: A systematic review

Angiology

Volumn 65, Issue 4, 2014, Pages 284-293

  Theocharidou, Eleni ^a   Gossios, Thomas D ^a   Giouleme, Olga ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

atherosclerosis; cardiovascular disease; carotid intima media thickness; inflammatory bowel diseases

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE;

ARTERIAL WALL THICKNESS; ARTERY WALL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROHN DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GENDER; HUMAN; HYPERTENSION; INFLAMMATORY BOWEL DISEASE; OBESITY; PROSPECTIVE STUDY; REVIEW; SMOKING; SMOKING HABIT; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID INTIMA-MEDIA THICKNESS; INFLAMMATORY BOWEL DISEASES;

ADOLESCENT; ADULT; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84895458155     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713477471     Document Type: Review

References (55)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126
2. Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420 (6917). 868-874
3. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004 ; 350 (14). 1387-1397
4. Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander?. Curr Med Res Opin. 2008 ; 24 (1). 75-78
5. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004 ; 351 (25). 2599-2610
6. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 2008 ; 200 (1). 1-12
7. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol. 2010 ; 8 (4). 437-449
8. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum. 2002 ; 46 (4). 862-873
9. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349 (25). 2399-2406
10. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des. 2009 ; 15 (5). 479-489
11. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 ; 140 (6). 1785-1794
12. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011 ; 106 (4). 713-718
13. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986 ; 61 (2). 140-145
14. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001 ; 85 (3). 430-434
15. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009 ; 104 (6). 1445-1451
16. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005 ; 11 (3). 304-313
17. Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis?. Angiology. 2010 ; 61 (2). 198-204
18. Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 ; 22 (9). 839-846
19. van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res. 2007 ; 48 (12). 2640-2646
20. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res. 2002 ; 54 (3). 528-538
21. Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Detection of early atherosclerosis using the ultrasound parameters of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidaemia. Int Angiol. 2005 ; 24 (4). 395
22. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol. 2010 ; 25 (4). 394-398
23. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007 ; 23 (1). 75-80
24. Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2006 ; 10 (1). 7-11
25. Aloi M, Tromba L, Di Nardo G, et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr. 2012 ; 161 (4). 589-594
26. Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci. 2011 ; 56 (1). 197-202
27. Kayahan H, Sari I, Cullu N, et al. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci. 2012 ; 57 (8). 2137-2143
28. Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007 ; 102 (2). 1050-1055
29. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007 ; 102 (3). 662-667
30. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008 ; 6 (1). 41-45
31. Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011 ; 5 (1). 41-47
32. Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study [published online September 26, 2012]. Gut. 2012 ;:
33. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011 ; 106 (4). 741-747
34. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012 ; 61 (11). 1619-1635
35. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 ; 24 (suppl 1). 2-9
36. Papa A, Bonizzi M, Andrisani G, Felice C, Mocci G, Gasbarrini A. Intima-media thickness in inflammatory bowel disease patients: a still open question. Am J Gastroenterol. 2008 ; 103 (2). 490-491
37. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004 ; 18 (3). 481-496
38. van der HF, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009 ; 15 (8). 1199-1207
39. van der Heide F, Dijkstra A, Albersnagel FA, Kleibeuker JH, Dijkstra G. Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. J Crohns Colitis. 2010 ; 4 (2). 125-131
40. Athyros VG, Tziomalos K, Katsiki N, et al. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE Study [published online November 7, 2012]. Curr Vasc Pharmacol. 2012 ;:
41. Ripolles PB, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006 ; 55 (7). 980-988
42. Toms TE, Panoulas VF, Douglas KM, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. Angiology. 2011 ; 62 (2). 167-175
43. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008 ; 23 (4). 370-378
44. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res. 2012 ; 51 (4). 314-324
45. Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis. 2006 ; 12 (1). 53-56
46. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007 ; 19 (12). 1070-1074
47. Oldenburg B, Fijnheer R, van der GR, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications?. Am J Gastroenterol. 2000 ; 95 (10). 2825-2830
48. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003 ; 36 (6). 431-441
49. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006 ; 113 (17). 2128-2134
50. Tanaskovic S, Isenovic ER, Radak D. Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy - evidence from clinical studies. Angiology. 2011 ; 62 (7). 535-542
51. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010 ; 69 (2). 325-331
52. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 ; 25 (10). 567-579
53. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 ; 32 (14). 1769-1818
54. Crockett SD, Hansen RA, Stürmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012 ; 18 (6). 1048-1056
55. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One. 2009 ; 4 (5). e5263